Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With Deeming Rule Pending, FDA Reminds E-Cigarette Firms About Drug Claims

This article was originally published in The Tan Sheet

Executive Summary

In a proposed rule, FDA describes to a new audience its long-established policy on drugs and devices marketed for off-label indications. The agency says “some ambiguity surrounds the circumstances” that determine whether a product is regulated as tobacco or as a drug, device or combination product

Advertisement

Related Content

US-Canada Pilot Could Help FDA's OTC Monograph Update Fly
E-Cigarette ‘Deeming’ Rule In OMB Review As Health Groups Urge Claim Enforcement
FDA Floats Broader Pathway For Nicotine Replacement Therapies
In Brief
Smoking Cessation Claims For E-Cigarettes Draw FDA Warnings

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

PS107925

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel